Intech Biopharm Ltd (6461) - Total Liabilities
Based on the latest financial reports, Intech Biopharm Ltd (6461) has total liabilities worth NT$1.25 Billion TWD (≈ $39.38 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Intech Biopharm Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Intech Biopharm Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Intech Biopharm Ltd to evaluate short-term liquidity relative to the company's equity base.
Intech Biopharm Ltd Competitors by Total Liabilities
The table below lists competitors of Intech Biopharm Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oroco Resource Corp
V:OCO
|
Canada | CA$3.56 Million |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
USA | $27.67 Million |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
Thailand | ฿4.32 Billion |
|
XAC Automation
TWO:5490
|
Taiwan | NT$458.60 Million |
|
Golden Bridge Electech Inc
TW:6133
|
Taiwan | NT$822.99 Million |
|
Forsys Metals Corp.
TO:FSY
|
Canada | CA$358.54K |
|
Pc Iletisim ve Medya Hizmetleri Sanayi Ticaret AS
IS:PCILT
|
Turkey | TL2.58 Billion |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
USA | $795.79K |
Liability Composition Analysis (2017–2025)
This chart breaks down Intech Biopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Intech Biopharm Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Intech Biopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Intech Biopharm Ltd (2017–2025)
The table below shows the annual total liabilities of Intech Biopharm Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.25 Billion ≈ $39.38 Million |
-20.96% |
| 2024-12-31 | NT$1.58 Billion ≈ $49.83 Million |
+2.48% |
| 2023-12-31 | NT$1.54 Billion ≈ $48.62 Million |
+1.61% |
| 2022-12-31 | NT$1.52 Billion ≈ $47.85 Million |
+20.16% |
| 2021-12-31 | NT$1.26 Billion ≈ $39.82 Million |
-2.22% |
| 2020-12-31 | NT$1.29 Billion ≈ $40.73 Million |
+24.70% |
| 2019-12-31 | NT$1.04 Billion ≈ $32.66 Million |
+1.20% |
| 2018-12-31 | NT$1.02 Billion ≈ $32.27 Million |
+15.42% |
| 2017-12-31 | NT$887.48 Million ≈ $27.96 Million |
-- |
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more